TGF-β1 production by CALRdel52 cells was dependent on JAK1/2, PI3K and ERK activity, thereby identifying these kinases as potential therapeutic targets to counteract the immunosuppressive effects of TGF-β in CALRdel52 MPN. This evidence concerns the gene JAK1 and myeloproliferative neoplasm.